Lisa Pieri

List of Publications by Year
in descending order

78 papers	5,686 citations	87888 38 h-index	76900 74 g-index
80 all docs	80 docs citations	80 times ranked	4654 citing authors

#	Article	IF	Citations
1	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	4.1	53
2	Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. American Journal of Hematology, 2019, 94, 845-852.	4.1	5
3	Validation of the Mayo alliance prognostic system for mastocytosis. Blood Cancer Journal, 2019, 9, 18.	6.2	6
4	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncology, 2018, 14, 2713-2723.	2.4	9
5	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	1.4	52
6	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. American Journal of Hematology, 2017, 92, E5-E6.	4.1	45
7	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	4.1	41
8	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	4.1	47
9	MR Imaging in nonâ€hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. American Journal of Hematology, 2016, 91, 1062-1063.	4.1	1
10	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. American Journal of Hematology, 2016, 91, 692-699.	4.1	54
11	Improving prognostic tools in systemic mastocytosis: Insights from mutations. American Journal of Hematology, 2016, 91, 867-868.	4.1	1
12	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
13	Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. Genomics Data, 2015, 5, 1-2.	1.3	5
14	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHOâ€criteria and stratified by calendar period of diagnosis. American Journal of Hematology, 2015, 90, 434-437.	4.1	19
15	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 2015, 125, 3352-3353.	1.4	41
16	Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis. Haematologica, 2015, 100, 757-767.	3.5	9
17	Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. Cancer Research, 2015, 75, 4753-4765.	0.9	41
18	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	12.8	145

#	Article	IF	Citations
19	Ruxolitinibâ€induced reversal of alopecia universalis in a patient with essential thrombocythemia. American Journal of Hematology, 2015, 90, 82-83.	4.1	56
20	Abnormal expression patterns ofWT1-as, MEG3andANRILlong non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	1.3	14
21	Givinostat for the treatment of polycythemia vera. Expert Opinion on Orphan Drugs, 2014, 2, 841-850.	0.8	1
22	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	1.4	340
23	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	4.1	165
24	Cerebral vein thrombosis in patients with <scp>P</scp>hiladelphiaâ€negative myeloproliferative neoplasms An <scp>E</scp>uropean <scp>L</scp>eukemia <scp>N</scp>et study. American Journal of Hematology, 2014, 89, E200-5.	4.1	42
25	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 2014, 167, 541-546.	2.5	47
26	Imaging studies in extramedullary hematopoiesis of the spleen. Annals of Hematology, 2014, 93, 347-349.	1.8	2
27	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	1.4	115
28	Masked polycythemia Vera (mPV): Results of an international study. American Journal of Hematology, 2014, 89, 52-54.	4.1	130
29	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	7.2	66
30	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 2014, 123, 1552-1555.	1.4	346
31	Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. American Journal of Hematology, 2014, 89, 438-442.	4.1	9
32	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia, 2014, 28, 1811-1818.	7.2	75
33	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	1.4	575
34	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014, 123, 1833-1835.	1.4	95
35	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 2014, 124, 3021-3023.	1.4	112
36	The burden of symptoms in myelofibrosis: From patient-reported outcomes to health economics. Leukemia Research, 2013, 37, 855-856.	0.8	3

#	Article	IF	Citations
37	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
38	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica, 2013, 98, e101-e102.	3.5	24
39	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	1.4	2
40	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. Blood, 2013, 122, 1582-1582.	1.4	1
41	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. Blood, 2013, 122, 1583-1583.	1.4	4
42	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. Blood, 2013, 122, 4068-4068.	1.4	10
43	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. PLoS ONE, 2013, 8, e77819.	2.5	9
44	Masked Polycythemia Vera (mPV): Results Of An International Study. Blood, 2013, 122, 1581-1581.	1.4	0
45	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	1.4	0
46	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncology, 2012, 8, 575-593.	2.4	4
47	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood, 2012, 119, 2239-2241.	1.4	90
48	Risk of second cancers in chronic myeloproliferative neoplasms. Blood, 2012, 119, 3861-3862.	1.4	14
49	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	4.1	105
50	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	4.1	107
51	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. Blood, 2012, 120, 804-804.	1.4	6
52	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. Blood, 2012, 120, 2849-2849.	1.4	0
53	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2011, 2, 21-32.	2.5	82
54	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	1.4	144

#	Article	IF	Citations
55	Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood, 2011, 118, 3445-3446.	1.4	32
56	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	1.4	153
57	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. Annals of Hematology, 2011, 90, 365-366.	1.8	6
58	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood, 2011, 118, 277-277.	1.4	7
59	Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,. Blood, 2011, 118, 3835-3835.	1.4	7
60	Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood, 2011, 118, 3852-3852.	1.4	1
61	The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,. Blood, 2011, 118, 3834-3834.	1.4	0
62	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2010, 85, 97-100.	4.1	48
63	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 2010, 95, 1435-1438.	3.5	41
64	Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Annals of Hematology, 2010, 89, 141-146.	1.8	39
65	Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. Annals of Hematology, 2010, 89, 745-746.	1.8	1
66	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010, 24, 1302-1309.	7.2	300
67	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	7.2	22
68	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	2.5	30
69	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2068-2073.	2.5	100
70	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	3.5	35
71	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	1.4	196
72	Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology, 2009, 2, 41-55.	2.2	6

#	Article	IF	Citations
73	The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica, 2009, 94, 1537-1545.	3.5	58
74	The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 2914-2914.	1.4	8
75	Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leukemia Research, 2008, 32, 516-517.	0.8	17
76	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	3.5	146
77	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	3.5	316
78	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. Blood, 2006, 108, 5-5.	1.4	14